Smartkarma AI Synthetic Expert Call Transcripts, Smartkarma

αSK SmartScripts

Smartkarma AI Synthetic Expert Call Transcripts

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.

<ul><li><strong style="font-weight:600;color:#1e293b;">Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the clinical superiority of bispecific antibody mechanisms over monotherapies, but shifting the global standard of care requires multi-regional Phase III validation across broader Western demographics.</strong></li><li><strong style="font-weight:600;color:#1e293b;">Akeso’s domestic growth remains robust with H1 2026 product sales reaching RMB 1,803.2 million, though NRDL price reductions have normalized gross margins to 79%; international enterprise value hinges on out-licensed royalty monetization and regulatory success, including Summit’s November 14, 2026 PDUFA decision.</strong></li><li><strong style="font-weight:600;color:#1e293b;">The HK$1.94 billion ($249 million) equity placement on October 13, 2026 at HK$97.76 per share reflects a proactive capital strategy to fully fund global registrational trials like COMPASSION-37 independently rather than relying solely on Western partners.</strong></li></ul><div style="color: #475569; background: #eee; border-radius: 16px; padding: 14px; margin: 14px 0; font-size: 12px; line-height: 16px;"><p style="color: #333; margin-bottom: 4px; font-style: italic; font-size: 12px; line-height: 16px;">Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.</p></div>

Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the clinical superiority of bispecific antibody mechanisms over monotherapies, but shifting the global standard of care requires multi-regional Phase III validation across broader Western demographics.Akeso’s domestic growth remains robust with H1 2026 product sales reaching RMB 1,803.2 million, though NRDL price reductions have normalized gross margins to 79%; international enterprise value hinges on out-licensed royalty monetization and regulatory success, including Summit’s November 14, 2026 PDUFA decision.The HK$1.94 billion ($249 million) equity placement on October 13, 2026 at HK$97.76 per share reflects a proactive capital strategy to fully fund global registrational trials like COMPASSION-37 independently rather than relying solely on Western partners.Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.

Akeso (9926 HK): Synthetic Expert Call Transcript (14 Oct 2026)

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shenzhen Salubris Pharmaceuticals / Equity Capital Markets

The company is a leading Chinese pharmaceutical company focused on the Cardiovascular-Kidney-Metabolic (CKM) sector, engaged in R&D, production, and sales of pharmaceuticals and medical devices. It is seeking a primary listing on the HKEX, having been listed on the Shenzhen Stock Exchange since 2009.

Shenzhen Salubris Pharmaceuticals (SLBRS HK)

<ul>
<li>Salubris, a CKM-focused innovative pharmaceutical company, is seeking an A+H listing. GS, Citi and CITIC are the joint sponsors.</li>
<li>While our previous note covers the fundamentals of the company, in this note we look at its business development, 1H26 results and A-H premium moves.</li>
<li>We raise our A-H premium base case for the company, given the shift in peer A-H premiums.</li>
</ul>


Salubris, a CKM-focused innovative pharmaceutical company, is seeking an A+H listing. GS, Citi and CITIC are the joint sponsors.
While our previous note covers the fundamentals of the company, in this note we look at its business development, 1H26 results and A-H premium moves.
We raise our A-H premium base case for the company, given the shift in peer A-H premiums.


Salubris (信立泰) A+H Pre-IPO: 1H26 Results Update

Independent Equity Research & Structured Analysis, VASRO GmbH

VASRO GmbH

Independent Equity Research & Structured Analysis

VASRO Equity Research Reports provide independent, structured analysis on listed companies, with a focus on public small- and mid-cap issuers, under-covered companies, and cross-border equity stories. Reports typically include company positioning, sector context, financial and strategic analysis, key investor-relevant developments, methodology, and disclosure documentation. Coverage is maintained through recurring and event-driven updates. there are 2 types of ERs, deep-dive rated equity research and non-rated equity research.

Sirnaomics is an RNA therapeutics biopharmaceutical company that discovers and develops innovative drugs for indications with unmet medical needs. The company leverages its proprietary polypeptide nanoparticle (PNP) and GalNAc RNAi platforms (GalAhead™) to build a pipeline of drug candidates, including STP705 and STP707 for oncology and fibrosis, and STP122G for anticoagulant therapies. Headquartered in Gaithersburg, MD, United States, the company was founded in 2007.

<ul><li>VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company’s announcement of 6 October 2026 and the FDA’s written responses of 10 September.</li><li>A state-owned fund, Guangzhou Guangjian, has paid RMB30m for 5.66% of RNAimmune’s Guangzhou subsidiary, and the deal was completed on 6 October. The price was set on an independent valuation of US$65.5m for RNAimmune Inc., the vaccine company in which Sirnaomics holds 60.21%. The money funds the subsidiary’s mRNA vaccine pipeline.</li><li>STP705, Sirnaomics’ lead drug for skin cancer, combines two gene-silencing molecules in one drug. In its written responses the FDA calls a four-arm Phase 2b study reasonable as an exploratory trial. The study compares the combination with each molecule alone and with placebo, and its results will shape the confirmatory Phase 3, the study on which approval rests.</li></ul>

VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company’s announcement of 6 October 2026 and the FDA’s written responses of 10 September.A state-owned fund, Guangzhou Guangjian, has paid RMB30m for 5.66% of RNAimmune’s Guangzhou subsidiary, and the deal was completed on 6 October. The price was set on an independent valuation of US$65.5m for RNAimmune Inc., the vaccine company in which Sirnaomics holds 60.21%. The money funds the subsidiary’s mRNA vaccine pipeline.STP705, Sirnaomics’ lead drug for skin cancer, combines two gene-silencing molecules in one drug. In its written responses the FDA calls a four-arm Phase 2b study reasonable as an exploratory trial. The study compares the combination with each molecule alone and with placebo, and its results will shape the confirmatory Phase 3, the study on which approval rests.

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705

APAC IPOs & Placements, Aequitas Research

Nicholas Tan

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/akeso-inc" target="_blank" data-smartkarma-citation="entities:28830:1" rel="noopener">Akeso (9926 HK) </a>is looking to raise around US$250m in a primary offering.</li>
<li>Recent deals over the last couple of years have been weak though this raise is a lot less opportunistic than prior deals.</li>
<li>In this note, we talk about the deal dynamics and run the deal through our ECM framework.</li>
</ul>



Akeso (9926 HK) is looking to raise around US$250m in a primary offering.
Recent deals over the last couple of years have been weak though this raise is a lot less opportunistic than prior deals.
In this note, we talk about the deal dynamics and run the deal through our ECM framework.


Aequitas: Akeso Inc Placement Past Deals Have Been Weak but Current Raise Is Less Opportunistic

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.

<ul>
<li>WuXi Bio launched a Placement,aiming to raise up to US$500mn.After a significant surge, selling shares at this share price level indicates a feature of cashing out at a high price. </li>
<li>Based on HK$51.77-52.31 and 2026 forecast, P/E is 32-33x, higher than our estimate 25-30x P/E.This means the market has already priced in most of growth for WuXi Bio this year.</li>
<li>Although Wuxi's affiliated companies have demonstrated solid fundamentals and signs of valuation recovery since 2025, the share reduction by major shareholders has still weakened market confidence in their long-term value</li>
</ul>


WuXi Bio launched a Placement,aiming to raise up to US$500mn.After a significant surge, selling shares at this share price level indicates a feature of cashing out at a high price. 
Based on HK$51.77-52.31 and 2026 forecast, P/E is 32-33x, higher than our estimate 25-30x P/E.This means the market has already priced in most of growth for WuXi Bio this year.
Although Wuxi's affiliated companies have demonstrated solid fundamentals and signs of valuation recovery since 2025, the share reduction by major shareholders has still weakened market confidence in their long-term value


Wuxi Biologics (2269 HK) Placement - Thought on Valuation and the Outlook